Oakwood's Products

Oakwood Laboratories maintains a strong proactive effort focusing on the in and out licensing of products and technology. We actively search for products and technology that align with the therapeutic markets of urology, oncology and endocrinology. We are seeking development and marketing partners for the following products/projects:

Products
Diseases
Status
License Availability
Leuprolide 14-day-kit prostate cancer Approved Outside N. America
Leuprolide 3.75 mg (1 month depot) prostate cancer pre-clinical Outside N. America
Leuprolide 7.5 mg (1 month depot) prostate cancer NDA Submission Outside N. America
Leuprolide 22.5 mg (3 month depot) prostate cancer NDA Submission Outside N. America
Leuprolide 30 mg (4 month depot) prostate cancer pre-clinical Outside N. America
Leuprolide 45 mg (6 month depot) prostate cancer pre-clinical Outside N. America
Octreotide (1 month depot) acromegaly pre-clinical World
Risperidone schizophrenia pre-clinical World
Dermal fill cosmetic pre-clinical World
Oakwood Labs

Oakwood Laboratories was founded as the research division of Ben Venue Laboratories, the largest and most experienced parenteral company in the world. In 1997 it was spun off as a separate entity when Ben Venue was acquired by Boehringer-Ingelheim. Oakwood's founders, Edward C. Smith and Mark T. Smith were C.E.O and the Director of Business Development of Ben Venue and were responsible for starting Ben Venue's generic division, Bedford Laboratories.